Outlook Therapeutics, Inc.
OTLK
$1.37
-$0.02-1.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -22.86% | 11.79% | |||
| Gross Profit | 22.86% | -11.79% | |||
| SG&A Expenses | 15.38% | 23.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.55% | 16.94% | |||
| Operating Income | 5.55% | -16.94% | |||
| Income Before Tax | 205.34% | -87.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 205.34% | -87.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 205.34% | -87.18% | |||
| EBIT | 5.55% | -16.94% | |||
| EBITDA | 5.56% | -16.97% | |||
| EPS Basic | 198.92% | -87.45% | |||
| Normalized Basic EPS | 195.04% | -83.53% | |||
| EPS Diluted | 198.92% | 127.11% | |||
| Normalized Diluted EPS | 195.04% | -81.93% | |||
| Average Basic Shares Outstanding | 2.14% | 2.15% | |||
| Average Diluted Shares Outstanding | 2.14% | -6.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||